CSIMarket Company Name, Ticker, Suppliers, else..
 
Galmed Pharmaceuticals Ltd   (NASDAQ: GLMD)
Other Ticker:  
 
 
Price: $2.5100 $0.01 0.400%
Day's High: $2.54 Week Perf: 41.78 %
Day's Low: $ 2.15 30 Day Perf: -4.2 %
Volume (M): 696 52 Wk High: $ 23.80
Volume (M$): $ 1,746 52 Wk Avg: $3.75
Open: $2.49 52 Wk Low: $1.67



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 0
 Employees 40
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd is a pharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of liver diseases. The company is based in Israel and operates globally.

Galmed is primarily known for its lead product candidate, Aramchol, which is under investigation for the treatment of non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease. Aramchol has shown promising results in clinical trials and has the potential to address the large unmet medical need in the NASH market.

In addition to Aramchol, Galmed is also engaged in the development of other drug candidates targeting liver diseases, including fibrosis and primary sclerosing cholangitis. The company's pipeline is focused on addressing various stages and aspects of liver disease progression.

Galmed has strategic partnerships and collaborations with other pharmaceutical companies to explore the potential of its drug candidates in combination therapies and to expand its global reach. The company has a strong commitment to research and development, aiming to bring innovative therapies to patients with liver diseases.


   Company Address: 16 Abba Hillel Road Ramat Gan 5250608
   Company Phone Number: 693.8448   Stock Exchange / Ticker: NASDAQ GLMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.31% 
AZN        1.98% 
JNJ   -0.03%    
MRK   -0.74%    
NVS        3.3% 
SNY        2.46% 
• View Complete Report
   



Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp disclosed a stunning -31.675 %, in revenue, during the fourth quarter of 2024

Declining demand caused an increase in deficit for the financial span ending December 31 2024, Tonix Pharmaceuticals Holding Corp s' deficit per share inched up to $-5.41 from $-105.08 where Revenue fell by -31.675 % to $2.58 million from $3.78 million a year ago. The deterioration of revenue is not comparable to relative to all in all Major Pharmaceutical Preparations sector, which posted a top-line growth during the same period.

Kronos Bio Inc

A shortfall of $-0.41 per Share at the Kronos Bio Inc in the fiscal fourth quarter of 2024

For the fiscal fourth quarter of 2024 KRON lost money of $-0.41 per share compare to $-0.42 a year prior and grew shortfall from $-0.23 per share from the prior reporting period. The revenue decreased by -0.7 % to $2.27 million from $2.29 million in the similar reporting period a year prior and sequentially Revenue decreased by -4.219 % from $2.37 million.

Exicure Inc

Working expenses were on the rise at the XCUR in the fourth quarter of 2024 earnings season

Following the large companies in the Major Pharmaceutical Preparations sector, a number of lesser known businesses are publishing the numbers. XCUR revealed it has booked operating shortfall of $-7.589 million, for the fourth quarter of 2024.

Liquidia Corporation

The Top-line plunged at LQDA in the fourth quarter of 2024 earnings season

the Major Pharmaceutical Preparations company declared disappointing Dec 31 2024 report, where Revenue melted down by -35.621 % to $2.92 million and the Liquidia Corporation recorded net loss per share to $-0.39, compared to $-0.42, in the comparable interval a year before. In contrast to the the LQDAs' scenario the remainder ofMajor Pharmaceutical Preparations sector, recorded a revenue 11.88% improvement from the comparable quarter a year ago in the fourth quarter of 2024.

Hutchmed China Limited

The unpleasant -24.797 % fall in revenue at the Major Pharmaceutical Preparations company all along the fourth quarter of 2024 earnings season

Revenue contraction of -24.797 % caused fall in profits by -66.67 % for the financial three months closing Dec 31 2024. HCM posted earnings of $630.20 million in Revenue this compares to $838.00 million a year prior and eps of $0.04 per share from 0.12 in the prior year. On the contrary to the Major Pharmaceutical Preparations company's scenario the all in allMajor Pharmaceutical Preparations industry, posted a revenue 11.88% gain compared to the similar period a year before in the fourth quarter of 2024.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com